Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0.00 Increased by +100.00% | -0.99 Increased by +100.00% |
| Jan 9, 24 | -0.98 Decreased by -13.95% | -0.85 Decreased by -15.29% |
| Oct 30, 23 | -0.80 Decreased by -2.56% | -0.82 Increased by +2.44% |
| Jul 31, 23 | -0.70 Decreased by -18.64% | -0.88 Increased by +20.45% |
| May 2, 23 | -0.98 Decreased by -75.00% | -0.81 Decreased by -20.99% |
| Mar 28, 23 | -0.86 Decreased by -68.63% | -0.81 Decreased by -6.17% |
| Nov 7, 22 | -0.78 Decreased by -81.40% | -0.65 Decreased by -20.00% |
| Aug 1, 22 | -0.59 Decreased by -78.79% | -0.60 Increased by +1.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by N/A% | -34.88 M Decreased by -44.73% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -28.43 M Decreased by -27.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.89 M Decreased by -46.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -28.07 M Decreased by -71.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -24.10 M Decreased by -63.85% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -22.30 M Decreased by -76.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -17.04 M Decreased by -102.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -16.33 M Decreased by -179.08% | Decreased by N/A% Decreased by N/A% |